非霍奇金淋巴瘤-话题@MedSci

[GetTopicListResponse(id=1220422, encodeId=7825122042280, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>, objectTitle=Clin Cancer Res：复发/转移性非霍奇金淋巴瘤采用维奈托克治疗的长期预后, objectType=article, longId=215143, objectId=f0e9215143b8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202181/1627792002241_2110107.JPG, objectUrl=/article/show_article.do?id=f0e9215143b8, replyNumber=0, likeNumber=0, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e9215143b8, moduleTitle=Clin Cancer Res：复发/转移性非霍奇金淋巴瘤采用维奈托克治疗的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0e9215143b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220421, encodeId=d285122042145, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>, objectTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, objectType=article, longId=726862, objectId=923fe2686288, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220512/a1a3fe2b61e14b48b109eb440bc5db62.jpg, objectUrl=/article/show_article.do?id=923fe2686288, replyNumber=0, likeNumber=166, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=923fe2686288, moduleTitle=通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=923fe2686288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220420, encodeId=da16122042083, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>, objectTitle=BJH：惰性非霍奇金淋巴瘤幸存者的持续疲劳症状、神经病变和角色功能障碍：一项纵向 PROFILES 登记研究, objectType=article, longId=724315, objectId=9bfce2431530, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=9bfce2431530, replyNumber=0, likeNumber=92, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bfce2431530, moduleTitle=BJH：惰性非霍奇金淋巴瘤幸存者的持续疲劳症状、神经病变和角色功能障碍：一项纵向 PROFILES 登记研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bfce2431530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220419, encodeId=a1bf122041906, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>, objectTitle=Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤, objectType=article, longId=293438, objectId=5c862934382f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202214/1641305917987_2110107.JPG, objectUrl=/article/show_article.do?id=5c862934382f, replyNumber=0, likeNumber=88, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c862934382f, moduleTitle=Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c862934382f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1220418, encodeId=597c122041843, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>, objectTitle=Clin Cancer Res：维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果, objectType=article, longId=216691, objectId=f8e221669147, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202194/1630722439933_2110107.JPG, objectUrl=/article/show_article.do?id=f8e221669147, replyNumber=0, likeNumber=101, createdTime=2022-05-17, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e221669147, moduleTitle=Clin Cancer Res：维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e221669147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1194344, encodeId=e387119434427, content=侵袭性B细胞<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a>患者接受<a href='/topic/show?id=aa081e4811f' target=_blank style='color:#2F92EE;'>#Tisagenlecleucel#</a>治疗并不优于标准疗法！看来不容易呀, objectTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, objectType=article, longId=298991, objectId=961f298991d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022217/1645056106902_1739456.jpg, objectUrl=/article/show_article.do?id=961f298991d8, replyNumber=0, likeNumber=139, createdTime=2022-02-17, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961f298991d8, moduleTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961f298991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非霍奇金淋巴瘤

2020-05-29

赛华佗 (审核中...)

前往app查看评论内容

#非霍奇金淋巴瘤#

Clin Cancer Res：复发/转移性非霍奇金淋巴瘤采用维奈托克治疗的长期预后

2022-05-17

赛华佗 (审核中...)

前往app查看评论内容

#非霍奇金淋巴瘤#

通用型CAR-T细胞CB-010治疗复发/难治性B细胞非霍奇金淋巴瘤，初步结果达到100%ORR和80%CR

2022-05-17

赛华佗 (审核中...)

前往app查看评论内容

#非霍奇金淋巴瘤#

BJH：惰性非霍奇金淋巴瘤幸存者的持续疲劳症状、神经病变和角色功能障碍：一项纵向 PROFILES 登记研究

2022-05-17

赛华佗 (审核中...)

前往app查看评论内容

#非霍奇金淋巴瘤#

Clin Cancer Res：采用抗CD79B抗体药物偶联物DCDS0780A治疗非霍奇金淋巴瘤

2022-05-17

赛华佗 (审核中...)

前往app查看评论内容

#非霍奇金淋巴瘤#

Clin Cancer Res：维奈托克单药治疗复发/难治性非霍奇金淋巴瘤的长期随访结果

2022-05-17

医者仁者 (审核中...)

前往app查看评论内容

侵袭性B细胞#非霍奇金淋巴瘤#患者接受#Tisagenlecleucel#治疗并不优于标准疗法！看来不容易呀

NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较

2022-02-17

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#非霍奇金淋巴瘤#

科室

工具

服务